Mark J. Gemkow

483 citations

15 papers · 392 · h-index 11

Impact in

Pharmacology top 10%
- Cannabis and Cannabinoid Research
Sensory Systems top 10%

Papers in

Molecular Biology 10
- Pharmacological Receptor Mechanisms and Effects 5
- Receptor Mechanisms and Signaling 3
Pharmacology 8
- Cannabis and Cannabinoid Research 7

Co-authors: Adam J. Davenport (4 shared papers)David J. Hallett (2 shared papers)Bart Ellenbroek (1 shared paper)Andrea M. Cesura (1 shared paper)Doris Riether (7 shared papers)David Thomson (7 shared papers)Lifen Wu (5 shared papers)Andreas Ebneth (3 shared papers)
Journals: Bioorganic & Medicinal Chemistry Letters (9 papers)Bioorganic & Medicinal Chemistry (1 paper)Assay and Drug Development Technologies (1 paper)Drug Discovery Today (1 paper)SLAS DISCOVERY (1 paper)
Partner nations: Germany United States United Kingdom

In The Last Decade

Mark J. Gemkow

15 papers receiving 379 citations

Peers

Countries citing papers authored by Mark J. Gemkow

Since Specialization

Citations

This map shows the geographic impact of Mark J. Gemkow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Gemkow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Gemkow more than expected).

Fields of papers citing papers by Mark J. Gemkow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Gemkow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Gemkow. The network helps show where Mark J. Gemkow may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark J. Gemkow, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark J. Gemkow Line = papers co-authored together Mark J. Gemkow links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work
1	The histamine H3 receptor as a therapeutic drug target for CNS disorders Drug Discovery Today ·Mark J. Gemkow, Adam J. Davenport, Silke Harich, Bart Ellenbroek, Andrea M. Cesura, David J. Hallett	2009	154
2	Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers Scientific Reports ·Adam J. Davenport, Ioana Berindan‐Neagoe, Nico Bräuer, Markus Koch, Andrea Rotgeri, Jens Nagel, Alexis Laux‐Biehlmann, Frederic Machet, Anne-Marie Coelho, Susan Boyce, Nikisha Carty, Mark J. Gemkow, Stephen D. Hess, Thomas M. Zollner, Oliver M. Fischer	2021	43
3	An orally bioavailable positive allosteric modulator of the mGlu4 receptor with efficacy in an animal model of motor dysfunction Bioorganic & Medicinal Chemistry Letters ·Stephen P. East, Samantha J. Bamford, Matthias G. A. Dietz, Christian Eickmeier, Adam Flegg, Boris Ferger, Mark J. Gemkow, Ralf Heilker, Bastian Hengerer, Adrian Kotey, Pui L. Loke, Gerhard Schänzle, Hans-Dieter Schubert, John R. Scott, Mark Whittaker, Mildred Williams, Przemysław Zawadzki, Kai Gerlach	2010	36
4	Exploiting differences in caspase-2 and -3 S2 subsites for selectivity: Structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors Bioorganic & Medicinal Chemistry ·Michel Maillard, Frederick A. Brookfield, Stephen M. Courtney, Florence Eustache, Mark J. Gemkow, Rebecca K. Handel, Laura C. Johnson, Peter Johnson, Mark A. Kerry, Florian Krieger, Mirco Meniconi, Ignacio Muñoz-Sanjuán, Jordan J. Palfrey, Hyunsun Park, Sabine Schaertl, Malcolm G. Taylor, Derek Weddell, Celia Dominguez	2011	29
5	Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity Bioorganic & Medicinal Chemistry Letters ·Monika Ermann, Doris Riether, Edward R. Walker, Innocent Mushi, James E. Jenkins, Beatriz Noya-Marino, Mark L. Brewer, Malcolm G. Taylor, Patricia Amouzegh, Stephen P. East, Brian Dymock, Mark J. Gemkow, Andreas F. Kahrs, Andreas Ebneth, Sabine Löbbe, Kathy O’Shea, Daw-Tsun Shih, David Thomson	2008	27
6	Selective CB2 receptor agonists. Part 1: The identification of novel ligands through computer-aided drug design (CADD) approaches Bioorganic & Medicinal Chemistry Letters ·Eugene R. Hickey, Renée Zindell, Pier F. Cirillo, Lifen Wu, Monika Ermann, Angela Berry, David Thomson, Claudia Albrecht, Mark J. Gemkow, Doris Riether	2014	19
7	Morpholine containing CB2 selective agonists Bioorganic & Medicinal Chemistry Letters ·Renée Zindell, Doris Riether, Todd Bosanac, Angela Berry, Mark J. Gemkow, Andreas Ebneth, Sabine Löbbe, Ernest Raymond, Diane Thome, Daw-Tsun Shih, David Thomson	2009	16
8	Selective CB2 receptor agonists. Part 2: Structure–activity relationship studies and optimization of proline-based compounds Bioorganic & Medicinal Chemistry Letters ·Doris Riether, Renée Zindell, Lifen Wu, Raj Betageri, James E. Jenkins, Someina Khor, Angela Berry, Eugene R. Hickey, Monika Ermann, Claudia Albrecht, Angelo Ceci, Mark J. Gemkow, N. Nagaraja, Helmut Romig, Achim Sauer, David Thomson	2014	13
9	1,4-Diazepane compounds as potent and selective CB2 agonists: Optimization of metabolic stability Bioorganic & Medicinal Chemistry Letters ·Doris Riether, Lifen Wu, Pier F. Cirillo, Angela Berry, Edward R. Walker, Monika Ermann, Beatriz Noya-Marino, James E. Jenkins, Dan Albaugh, Claudia Albrecht, Michael T. Fisher, Mark J. Gemkow, Heather Grbic, Sabine Löbbe, Clemens Möller, Kathy O’Shea, Achim Sauer, Daw-Tsun Shih, David Thomson	2011	13
10	Using Electrophysiology and In Silico Three-Dimensional Modeling to Reduce Human Ether-à-go-go Related Gene K ⁺ Channel Inhibition in a Histamine H3 Receptor Antagonist Program Assay and Drug Development Technologies ·Adam J. Davenport, Clemens Möller, Alexander Heifetz, Michael P. Mazanetz, Richard Law, Andreas Ebneth, Mark J. Gemkow	2010	12
11	Selective CB2 receptor agonists. Part 3: The optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model Bioorganic & Medicinal Chemistry Letters ·Alessandra Bartolozzi, Pier F. Cirillo, Angela Berry, Eugene R. Hickey, David Thomson, Lifen Wu, Renée Zindell, Claudia Albrecht, Angelo Ceci, Mark J. Gemkow, N. Nagaraja, Helmut Romig, Achim Sauer, Doris Riether	2014	12
12	Aryl 1,4-diazepane compounds as potent and selective CB2 agonists: Optimization of drug-like properties and target independent parameters Bioorganic & Medicinal Chemistry Letters ·Renée Zindell, Edward R. Walker, John Scott, Patricia Amouzegh, Lifen Wu, Monika Ermann, David Thomson, Micheal B. Fisher, Cody L. Fullenwider, Heather Grbic, Paul V. Kaplita, Brian Linehan, Mita Patel, Monica Patel, Sabine Löbbe, Svenja Block, Claudia Albrecht, Mark J. Gemkow, Daw-Tsun Shih, Doris Riether	2011	9
13	Discovery of substituted benzyl tetrazoles as histamine H3 receptor antagonists Bioorganic & Medicinal Chemistry Letters ·Adam J. Davenport, Christopher C. Stimson, Massimo Corsi, Darshan G. Vaidya, Edward P. Glenn, Timothy D. Jones, Sarah Bailey, Mark J. Gemkow, Ulrike Fritz, David J. Hallett	2010	5
14	A Label-Free LC/MS/MS-Based Enzymatic Activity Assay for the Detection of Genuine Caspase Inhibitors and SAR Development SLAS DISCOVERY ·Michel Maillard, Celia Dominguez, Mark J. Gemkow, Florian Krieger, Hyunsun Park, Sabine Schaertl, Dirk Winkler, Ignacio Muñoz-Sanjuán	2013	3
15	M20 Activation Of The Trkb Receptor Pathway Using A Novel Monoclonal Antibody Agonist: Implications For The Treatment Of Huntington's Disease Journal of Neurology Neurosurgery & Psychiatry ·Nikisha Carty, Laura S. Schmidt, Galina Bursow, Tom Schwagarus, Caroline Graff, Ewa Damrath, Kirsten Kuhlbrodt, Matthew F. Kohler, S. Koeplin, K. Salomon, S. Jäger, Mark J. Gemkow, H. von der Kammer, John Wityak, Ignacio Muñoz-Sanjuán, J. Bard	2014	1

About Mark J. Gemkow

Mark J. Gemkow is a scholar working on Molecular Biology, Pharmacology, Cellular and Molecular Neuroscience, Immunology and Toxicology, having authored 15 papers that have together received 392 indexed citations. Recurring topics across this work include Cannabis and Cannabinoid Research (7 papers), Pharmacological Receptor Mechanisms and Effects (5 papers), Neurotransmitter Receptor Influence on Behavior (4 papers), Mast cells and histamine (3 papers), Receptor Mechanisms and Signaling (3 papers), Forensic Toxicology and Drug Analysis (2 papers), Genetic Neurodegenerative Diseases (2 papers) and Neuroscience and Neuropharmacology Research (2 papers). The work is most often cited by research in Pharmacology (115 citations), Sensory Systems (30 citations), Cellular and Molecular Neuroscience (110 citations), Immunology (117 citations) and Biological Psychiatry (11 citations). Mark J. Gemkow has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Adam J. Davenport, David J. Hallett, Bart Ellenbroek, Andrea M. Cesura, Doris Riether, David Thomson, Lifen Wu, Andreas Ebneth, Renée Zindell and Monika Ermann. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Bioorganic & Medicinal Chemistry, Assay and Drug Development Technologies, Drug Discovery Today and SLAS DISCOVERY.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Mark J. Gemkow

Impact in

Papers in i

In The Last Decade

Mark J. Gemkow

Peers

Countries citing papers authored by Mark J. Gemkow

Fields of papers citing papers by Mark J. Gemkow

All Works

About Mark J. Gemkow

Explore authors with similar magnitude of impact

Papers in